MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates

AIDS Research and Human Retroviruses

Volumn 15, Issue 10, 1999, Pages 921-930

  Gorse, Geoffrey J ^a,k   Patel, Gira B ^a   Mandava, Mahendra ^a   Berman, Phillip W ^b   Belshe, Robert B ^a   Schwartz, David ^c   Clements Mann, Mary Lou ^c   Frey, Sharon E ^a   Mulligan, Mark ^d   Goepfert, Paul ^d   Evans, Thomas ^e   Keefer, Michael ^e   McElrath, M Julie ^f   Corey, Lawrence ^f   Graham, Barney S ^g   Wright, Peter ^g   Matthews, Thomas ^h   Bolognesi, Dani ^h   Walker, Mary Clare ⁱ   Grabowsky, Mark ⁱ   Stablein, Don ^j   more..

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VaxGen Inc   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j EMMES CORPORATION   (United States)

^k S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN GP 120;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; AIDS VACCINES; ANIMALS; CHO CELLS; CRICETINAE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MIDDLE AGED; VACCINATION; VACCINES, SYNTHETIC;

EID: 20244375525     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310638     Document Type: Article

References (16)

1. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twaddell T, Berman PW, Gregory T, Izu AE, Walker MC, and Fast PE, for the NIAID AIDS Vaccine Trials Network: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480.
2. IIIBrgp120 subunit vaccine. Lancet 1993;342:69-73.
3. Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, and Doms RW: Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 1996;70:753-762.
4. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
5. Gorse GJ, Frey SE, Newman FK, Belshe RB, and the NIAID AIDS Vaccine Clinical Trials Network: Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. J Clin Microbiol 1992;30:2606-2612.
6. Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB, and the NIAID AIDS Vaccine Clinical Trials Network: Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine 1994;12:912-918.
7. MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine 1998;16:493-506.
8. Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, and Matthews TJ, for the NIAID AIDS Vaccine Evaluation Group: Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. Clin Diagn Lab Immunol 1996;3:378-386.
9. Schwartz D, Clements ML, Belshe R, Gorse G, Izu A, Matthews T, and members of the NIAID AIDS Vaccine Evaluation Group: Antibody responses to neutralizing domains of gp120 in HIV (-) vaccinees boosted with homologous or heterologous rgp120. In: Abstract Book of the IXth International Conference on AIDS in Affiliation with the IVth STD World Congress (Berlin), Berlin. Congress Secretariat, Institute for Clinical and Experimental Virology of the Free University of Berlin, 1993, p. 249. [Abstract PO-A29-0690]
10. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MD, Wagner KF, McNeil JG, McCutchan FE, and Burke DS, for the National Institue of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340-348.
11. Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege A-M, Excler J-L, Hioe C, Kahn J, McElrath MJ, Shape S, Sinangil F, Steimer K, Walker MC, Wassef N, and Xu S: Neutralization of a clade B primary isolate by sera from HIV-uninfected recipients of candidate AIDS vaccines. J Infect Dis 1997;175:764-774.
12. SF-2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-1246.
13. Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, Wurm FM, and Gregory TJ: Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol 1992;66:4464-4469.
14. WHO Network for HIV Isolation and Characterization: HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: Genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Hum Retroviruses 1994;10:1327-1343.
15. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Margado M, Galvao-Castro B, Von Briesen H, Beddows S, Weber J, Sharp PM, Shaw GM, Hahn BH, and the WHO and NIAID Networks for HIV Isolation and Characterization: Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J Virol 1996;70:1651-1667.
16. Cecilia D, Kewalramani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, and Zolla-Pazner S: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998;72:6988-6996.